** Shares of drug developer Protagonist Therapeutics PTGX.O rise 9% to $41 premarket
** PTGX and Takeda 4502.T says its drug to treat a type of blood cancer met the main goal of proportion of patients achieving a response in a late-stage study
** Co says 77% of patients who were treated with the drug, rusfertide, responded to it, compared with 33% that received placebo
** Drug was tested in patients with the rare blood cancer, polycythemia vera, who require regular withdrawal of blood (phlebotomy) to manage their condition
** Co says there was no evidence of an increased risk of cancer in rusfertide-treated patients compared to those on placebo
** PTGX rose 23.5% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。